Health Care · Pharmaceutical Preparations · Nasdaq · CIK 25743 · FYE Dec 31 · Prices AT CLOSE 2026-07-29 (USD) — end-of-day, never a live or intraday quote
Last $2.06Day +0.00%Mkt cap $24M1Y +77.6%Off 52W high −29.9%Vol (1Y) 76.3%
Daily closing price, split-adjusted to the current basis; 3y shown of 4,012 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest0.4% of sh out |
| Days to cover1.6d |
| 13F net flow (QoQ)+0.45% |
| Top-10 13F concentration93.0% |
| Next report (est.)2026-08-12 |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| Sales (TTM)$3.4M |
| Earnings (TTM)$179,000 |
| ROE−2.1% |
| Net margin−18.8% |
| Sales growth 3Y−64.9% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD+26.4% |
| 1Y+77.6% |
| 3Y−49.3% |
| 5Y−96.0% |
| 10Y−99.5% |
| Since incept. (ann.)−19.1% |
Price return through 2026-07-29 · series begins 2010-01-12. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)76.3% |
| Ann. volatility (3Y)86.1% |
| Sharpe (1Y)1.12 |
| Sharpe (3Y)0.12 |
| Max drawdown (1Y)−34.3% |
| Max drawdown (3Y)−83.0% |
| Beta (3Y vs SPY)1.34 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| Rubric Capital Management LP | 1.2M | $2M | 10.30% | +0.0% |
| Clearline Capital LP | 635,222 | $1M | 5.49% | +0.0% |
| Squadron Capital Management LLC | 420,421 | $849,250 | 3.63% | new |
| VANGUARD CAPITAL MANAGEMENT LLC | 353,697 | $714,468 | 3.06% | new |
| Tejara Capital Ltd | 345,852 | $698,621 | 2.99% | −1.4% |
| ADAR1 Capital Management, LLC | 209,210 | $422,604 | 1.81% | +0.0% |
| RENAISSANCE TECHNOLOGIES LLC | 146,200 | $295,324 | 1.26% | +51.5% |
| MORGAN STANLEY | 129,217 | $261,018 | 1.12% | +0.0% |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-05-12 | $0.01 | — | $724,000 | +84.2% |
| 2025-12-31 | 2026-03-30 | — | — | $893,000 | +33.9% |
| 2025-09-30 | 2025-11-12 | $0.01 | — | $784,000 | +43.3% |
| 2025-06-30 | 2025-08-12 | $0.05 | — | $952,000 | +306.8% |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-08-12 is ESTIMATED from filing cadence (median gap 92d) — not company-confirmed.
US 59% · Non Us 41%
geographic · each slice's share of TAGGED segment revenue in the latest annual filing (XBRL, as filed). Untagged revenue is excluded from the denominator, so slices need not sum to consolidated sales.
